KYTX

Kyverna TherapeuticsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

Current thesis

KYTX has unusually near-dated biotech catalysts: dual AAN presentations in April 2026, a stated SPS BLA target in 1H 2026, and cash runway management says extends into 2028 while funding SPS launch prep and Phase 3 gMG execution [#8-K-2026-03-26] [#10-K-2026-03-26].

Posture

Mixed

Lead driver

Sentiment

What changed

Sentiment remains the lead driver in the composite, 7D delta +12.0.

What can break

Cash runway is guided into 2028, but burn remains high and future dilution risk is not eliminated if timelines extend or commercialization costs rise [#8-K-2026-03-26] [#10-K-2026-03-26].

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $10.50 · Bull $16.00 · Bear $5.50

Data freshness

Prices

As of 2026-07-18

Fundamentals

As of 2026-07-17 • Vendor: Data Vendor v1

Scores

As of 2026-07-18 • Model: HYBRID_IC_RP

AI Memo

As of 2026-04-15 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-18

Supporting evidence

What

Grade C · Mixed

Confidence Medium · Net Neutral

Target $30.40

Why

Momentum18 · Δ7d -37.9

Value41 · Δ7d -0.1

Sentiment84 · Δ7d +12.0

So what

Balanced signals (Net Neutral). Wait for confirmation before sizing up.

Lead driver: Sentiment · See AI snapshot

Momentum

26% active weight

Current posture

7d trendSoftening

Δ7d

-37.9

Δ21d

-2.4

Value

39% active weight

Current posture

7d trendFlat

Δ7d

-0.1

Δ21d

0.0

Sentiment

34% active weight

Current posture

7d trendImproving

Δ7d

+12.0

Δ21d

+13.9

Why this grade

Composite grade C. Momentum 18.0 / Value 41.1 / Sentiment 84.4

Fundamentals (TTM)

As of 2026-07-17

Market Cap

$452.93M

Beta

Shares Out

60.8M

P/E (TTM) · Derived

-2.0

P/S (TTM)

P/FCF (TTM) · Derived

-2.36

Rev YoY

-100.0%

EPS YoY

-36.3%

Gross Margin

-474.1%

Op Margin

Net Debt

-$250.22M

Current Ratio

8.15

As of 2026-07-18 • Updated nightlySource: Internal modelMethodology